Cardialen is developing a revolutionary implantable device therapy to treat Atrial Fibrillation (AF) that will improve the lives of people suffering from AF by restoring their natural heartbeat. Based on a breakthrough discovery by Dr. Igor Effimov at Washington University in St. Louis, Cardialen Therapy terminates AF in animals through an entirely new low-energy approach, a method that obviates the need for the painful high-energy shocks that hampered the adoption of prior implantable device therapies for AF. Yet a vexing unmet clinical need, AF is the most common sustained cardiac arrhythmia encountered in clinical practice, costing more than $26 billion dollars and 80,000 lives per year in the United States alone. In 2012, Cardialen completed preparations for the acute human clinical study planned in 2013.